A Platform Designed to Empower Quality Improvement for Patients with Atrial Fibrillation
- PMID: 40241409
- PMCID: PMC12178160
- DOI: 10.1097/JMQ.0000000000000231
A Platform Designed to Empower Quality Improvement for Patients with Atrial Fibrillation
Abstract
There are significant gaps in care for patients with atrial fibrillation (AF) and is a need to focus on improving guideline-concordant care. Recognizing challenges encountered in pursuing sustainable quality improvement (QI) in AF care, the Heart Rhythm Society spearheaded a multifaceted collaboration grounded in the principles of Improvement Science to develop a robust platform aimed specifically at demystifying QI for clinicians and health care systems interested in closing care gaps for patients with AF. Solution development included an innovative discovery process, a design phase, piloting, and refinement, and finished with transformation into a comprehensive digital platform. End-users were engaged throughout the 4-phase process to help ensure the final platform would meet the needs of clinicians and health care systems. The result was the launch of www.CardiQ.org featuring the Atrial Fibrillation QI Framework and an extensive, curated Resource Library that has been accessed by more than 10 000 users spanning over 100 countries.
Keywords: CardiQ; atrial fibrillation; digital; innovation; transformation.
Copyright © The Authors 2025.
Conflict of interest statement
Thomas F. Deering: Paid consultant or received honorarium from CVRx Inc., Pacemate, Sanofi, Boston Scientific, Abbott. John A. Gillespie: Former employee of Pfizer Inc. Julie Simonson: Employee and shareholder of Pfizer Inc. Julie Gouveia-Pisano: Employee and shareholder of Pfizer Inc. Heather Somand: Former employee of Pfizer Inc. Charles J Medico: Employee and shareholder of Pfizer Inc. Karl H. Schuleri: Employee and shareholder of Bristol Myers Squibb. Ramin Zand: Research (Contracted Grants for PIs and Named Investigators only), Heart Rhythm Society; NIH Grant. Sandeep K. Jain: Research (Contracted Grants for PIs and Named Investigators only), Medtronic and Boston Scientific. James C. Coons: Paid consultant or received honorarium from Pfizer and Bristol Myers Squibb. John N. Catanzaro: Honoraria/Speaking/Consulting Fee, Aziyo Biologics. All the other authors have no conflicts of interest to disclose.
Figures
References
-
- Shojania K, McDonald K, Wachter R, et al. Closing The Quality Gap: A Critical Analysis of Quality Improvement Strategies, Volume 1—Series Overview and Methodology. Technical Review 9 (Contract No. 290-02-0017 to the Stanford University-UCSF Evidence-based Practices Center). AHRQ Publication No. 04-0051-1. Agency for Healthcare Research and Quality; 2004. Accessed October 14, 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK43908/. - PubMed
-
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988. - PubMed
-
- Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229–234. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
